近日，一项发表于国际杂志the Annals of Surgery上的研究论文中，来自路易斯维尔大学（University of Louisville）的研究人员通过研究表示，在胰腺癌细胞中实施不可逆地电穿孔（IRE）或可改善某些患者的生存率。
研究者Robert Martin II博士表示，对胰腺癌患者进行手术完全移除癌症组织是不可能的，当前研究中我们对200名成年III期胰腺癌患者进行研究，在患者完成化疗后对其进行不可逆地电穿孔疗法。
结果显示，大约一半的患者出现了并发症，但研究者表示，IRE疗法所引发的副作用是最小的，而且副作用直接和手术操作相关，患者的平均生存仅为两年，而进行IRE疗法后或可使得某些患者的生存延长至7年。
研究者指出，对于III期局部恶性胰腺癌的病人而言，将IRE疗法同常规的化疗及放疗方法相结合或可有效改善并且延长胰腺癌患者的生存率，相关研究结果对于后期开发治疗胰腺癌的新型疗法提供了新的思路和希望。
doi:10.1097/SLA.0000000000001441
PMC:
PMID:
Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation: Safety and Efficacy
Martin, Robert C. G. II MD, PhD, FACS*; Kwon, David MD, FACS†; Chalikonda, Sricharan MD, FACS‡; Sellers, Marty MD, MPH, FACS§; Kotz, Eric MD¶; Scoggins, Charles MD, MBA, FACS*; McMasters, Kelly M. MD, PhD, FACS*; Watkins, Kevin MD, FACS∥
Objectives: Ablative therapies have been increasingly utilized in the treatment of locally advanced pancreatic cancer (LAPC). Irreversible electroporation (IRE) is an energy delivery system, effective in ablating tumors by inducing irreversible membrane destruction of cells. We aimed to demonstrate efficacy of treatment with IRE as part of multimodal treatment of LAPC. Methods: From July 2010 to October 2014, patients with radiographic stage III LAPC were treated with IRE and monitored under a multicenter, prospective institutional review board–approved registry. Perioperative 90-day outcomes, local failure, and overall survival were recorded. Results: A total of 200 patients with LAPC underwent IRE alone (n = 150) or pancreatic resection plus IRE for margin enhancement (n = 50). All patients underwent induction chemotherapy, and 52% received chemoradiation therapy as well for a median of 6 months (range, 5–13 months) before IRE. IRE was successfully performed in all patients. Thirty-seven percent of patients sustained complications, with a median grade of 2 (range, 1–5). Median length of stay was 6 days (range, 4–36 days). With a median follow-up of 29 months, 6 patients (3%) have experienced local recurrence. Median overall survival was 24.9 months (range: 4.9–85 months). Conclusions: For patients with LAPC (stage III), the addition of IRE to conventional chemotherapy and radiation therapy results in substantially prolonged survival compared with historical controls. These results suggest that ablative control of the primary tumor may prolong survival.